transmucosal drug delivery devices market size, transmucosal drug delivery devices market scope, transmucosal drug delivery devices market insights, transmucosal drug delivery devices market share, transmucosal drug delivery devices market analysis, transmucosal drug delivery devices market trends
How large is the transmucosal drug delivery devices market, and what is its growth trajectory?
The transmucosal drug delivery devices market size has grown strongly in recent years. It will grow from $50.24 billion in 2024 to $55.04 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to the need for rapid relief from angina, the effectiveness of sublingual delivery for quick absorption into the bloodstream, desire to bypass gastrointestinal degradation, development of buccal tablets, the need for non-invasive delivery of peptides and proteins.
The transmucosal drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $78.21 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to the development of smart drug delivery systems, increased prevalence of chronic diseases, growing focus on personalized medicine, aging population with higher medication needs, and increased awareness. Major trends in the forecast period include expansion in therapeutic applications, customizing drug delivery devices for personalized medicine, regulatory approvals and guidelines, emerging markets, eco-friendly devices, and innovative formulations.
Get Your Free Sample of The Global Transmucosal Drug Delivery Devices Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16812&type=smp
What are the key forces behind the transmucosal drug delivery devices market’s growth in recent years?
The growing prevalence of chronic diseases is expected to propel the growth of the transmucosal drug delivery devices market going forward. A chronic disease refers to a long-lasting condition that typically progresses slowly and persists over time, often requiring ongoing medical management to control symptoms and prevent complications. Chronic diseases are rising as a result of, lifestyle factors, aging populations, environmental factors, healthcare system challenges, and urbanization. Transmucosal drug delivery devices are used in chronic diseases to provide controlled and efficient delivery of medications, ensuring sustained therapeutic levels for managing symptoms and improving patient adherence. For instance, in August 2023, according to a report published by the Leukemia & Lymphoma Society (LLS), a US-based charitable organization, in the US, approximately every three minutes, someone is diagnosed with leukemia, lymphoma, or myeloma. In 2023, an estimated 184,720 individuals are expected to receive these diagnoses, representing 9.4% of the projected 1,958,310 new cancer cases for the year. Therefore, growing prevalence of chronic diseases is driving the transmucosal drug delivery devices market.
What are the major segments of the transmucosal drug delivery devices market?
The transmucosal drug delivery devices market covered in this report is segmented –
1) By Type: Passive Transdermal Drug Delivery, Active Transdermal Drug Delivery
2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films And Wafers, Gels, Medicated Confectionery, Other Drug Types
3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, Others Indications
4) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Hospitals
Subsegments:
1) By Passive Transdermal Drug Delivery: Reservoir Systems, Matrix Systems, Micro-Needle Systems, Pressure-Sensitive Adhesive Systems
2) By Active Transdermal Drug Delivery: Iontophoresis, Sonophoresis, Electroporation, Thermal Ablation, Microporation
Order your report now for swift delivery
Which companies dominate the transmucosal drug delivery devices market?
Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Becton Dickinson and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Lifevision Healthcare Private Limited, Noven Pharmaceuticals, SAVA Healthcare Limited, Antares Pharma Inc., Kaizen Pharmaceuticals Pvt. Ltd., Lucky Pharma Pvt. Ltd., Maya Biotech Pvt. Ltd, AdvaCare Pharma LLP, Satsuma Pharmaceuticals Inc., Biophar Lifesciences Private Limited, Fibovil Pharmaceuticals Private Limited, Slan Medicinal Holdings Ltd.
What major trends will shape the transmucosal drug delivery devices market during the forecast period?
Major companies operating in transmucosal drug delivery devices are developing innovative smart platform, such as proprietary transdermal patch delivery platforms that enhance drug absorption and improve patient compliance and convenience. Proprietary transdermal patch delivery platforms refer to specialized technologies owned by companies for administering medications through the skin, ensuring controlled release, and enhanced therapeutic outcomes. For instance, in January 2024, Starton Therapeutics Inc, a US-based biotechnology company, launched STARSILON, a novel proprietary transdermal patch delivery platform, for a longer duration to achieve therapeutic delivery of difficult-to-formulate APIs. It expands transdermal drug delivery options for challenging active pharmaceutical ingredients (APIs), enhancing therapeutic efficacy with sustained delivery rates.
What are the key regional dynamics of the transmucosal drug delivery devices market, and which region leads in market share?
North America was the largest region in the transmucosal drug delivery devices market in 2024. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Transmucosal Drug Delivery Devices Market Report 2025 Offer?
The transmucosal drug delivery devices market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Transmucosal drug delivery devices are medical devices designed to deliver drugs through the mucous membranes, such as those in the mouth, nose, or rectum, for rapid absorption into the bloodstream. These devices are used to administer medications that are poorly absorbed by the gastrointestinal tract or that require quick onset of action, such as pain relief or hormone therapy. Their purpose is to bypass the digestive system, providing a more direct and efficient route for drug delivery.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16812
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
